Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Quantifying atherogenic l… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

Artikel i vetenskaplig tidskrift
Författare M. R. Langlois
Bø G. Nordestgaard
A. Langsted
M. J. Chapman
K. M. Aakre
H. Baum
Jan Borén
E. Bruckert
A. Catapano
C. Cobbaert
P. Collinson
O. S. Descamps
C. J. Duff
A. Von Eckardstein
A. Hammerer-Lercher
P. R. Kamstrup
G. Kolovou
F. Kronenberg
S. Mora
K. Pulkki
A. T. Remaley
N. Rifai
E. Ros
S. Stankovic
A. Stavljenic-Rukavina
G. Sypniewska
G. F. Watts
Olov Wiklund
P. Laitinen
Publicerad i Clinical Chemistry and Laboratory Medicine
Volym 58
Nummer/häfte 4
Sidor 496-517
ISSN 1434-6621
Publiceringsår 2020
Publicerad vid Wallenberglaboratoriet
Institutionen för medicin
Sidor 496-517
Språk en
Länkar dx.doi.org/10.1515/cclm-2019-1253
Ämnesord apolipoprotein B, atherosclerotic cardiovascular disease, LDL cholesterol, lipoprotein(a), non-HDL cholesterol, remnant cholesterol
Ämneskategorier Kardiovaskulär medicin

Sammanfattning

The joint consensus panel of the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) recently addressed present and future challenges in the laboratory diagnostics of atherogenic lipoproteins. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDLC), LDL cholesterol (LDLC), and calculated non-HDLC (=total - HDLC) constitute the primary lipid panel for estimating risk of atherosclerotic cardiovascular disease (ASCVD) and can be measured in the nonfasting state. LDLC is the primary target of lipid-lowering therapies. For on-treatment follow-up, LDLC shall be measured or calculated by the same method to attenuate errors in treatment decisions due to marked between-method variations. Lipoprotein(a) [Lp(a)]-cholesterol is part of measured or calculated LDLC and should be estimated at least once in all patients at risk of ASCVD, especially in those whose LDLC declines poorly upon statin treatment. Residual risk of ASCVD even under optimal LDL-lowering treatment should be also assessed by non-HDLC or apolipoprotein B (apoB), especially in patients with mild-to-moderate hypertriglyceridemia (2-10 mmol/L). Non-HDLC includes the assessment of remnant lipoprotein cholesterol and shall be reported in all standard lipid panels. Additional apoB measurement can detect elevated LDL particle (LDLP) numbers often unidentified on the basis of LDLC alone. Reference intervals of lipids, lipoproteins, and apolipoproteins are reported for European men and women aged 20-100 years. However, laboratories shall flag abnormal lipid values with reference to therapeutic decision thresholds. © 2019 Walter de Gruyter GmbH, Berlin/Boston 2019.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?